| Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, MM Al-Hawary, MA Arain, YJ Chen, KK Ciombor, ... Journal of the National Comprehensive Cancer Network 19 (3), 329-359, 2021 | 1276 | 2021 |
| Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: a phase 2 clinical trial JE Murphy, JY Wo, DP Ryan, JW Clark, W Jiang, BY Yeap, LC Drapek, ... JAMA oncology 5 (7), 1020-1027, 2019 | 512 | 2019 |
| Rectal cancer, version 2.2022, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, MM Al-Hawary, N Azad, YJ Chen, KK Ciombor, ... Journal of the National Comprehensive Cancer Network 20 (10), 1139-1167, 2022 | 483 | 2022 |
| Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers AR Parikh, I Leshchiner, L Elagina, L Goyal, C Levovitz, G Siravegna, ... Nature medicine 25 (9), 1415-1421, 2019 | 467 | 2019 |
| NCCN guidelines insights: rectal cancer, version 6.2020: featured updates to the NCCN guidelines AB Benson, AP Venook, MM Al-Hawary, MA Arain, YJ Chen, KK Ciombor, ... Journal of the National Comprehensive Cancer Network 18 (7), 806-815, 2020 | 461 | 2020 |
| Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX T Michelakos, I Pergolini, C Fernández-del Castillo, KC Honselmann, ... Annals of surgery 269 (4), 733-740, 2019 | 344 | 2019 |
| Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer AR Parikh, EE Van Seventer, G Siravegna, AV Hartwig, A Jaimovich, Y He, ... Clinical Cancer Research 27 (20), 5586-5594, 2021 | 296 | 2021 |
| Genomic landscape of cell-free DNA in patients with colorectal cancer JH Strickler, JM Loree, LG Ahronian, AR Parikh, D Niedzwiecki, ... Cancer discovery 8 (2), 164-173, 2018 | 271 | 2018 |
| Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial AR Parikh, A Szabolcs, JN Allen, JW Clark, JY Wo, M Raabe, H Thel, ... Nature cancer 2 (11), 1124-1135, 2021 | 194 | 2021 |
| Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials E Liu, ME Schmidt, R Margolin, R Sperling, R Koeppe, NS Mason, ... Neurology 85 (8), 692-700, 2015 | 175 | 2015 |
| Using circulating tumor DNA in colorectal cancer: current and evolving practices M Malla, JM Loree, PM Kasi, AR Parikh Journal of Clinical Oncology 40 (24), 2846-2857, 2022 | 165 | 2022 |
| Small bowel adenocarcinoma, version 1.2020, NCCN clinical practice guidelines in oncology AB Benson, AP Venook, MM Al-Hawary, MA Arain, YJ Chen, KK Ciombor, ... Journal of the National Comprehensive Cancer Network 17 (9), 1109-1133, 2019 | 147 | 2019 |
| Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events YR Badran, JV Cohen, PK Brastianos, AR Parikh, TS Hong, M Dougan Journal for immunotherapy of cancer 7, 1-11, 2019 | 139 | 2019 |
| Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer ZA Wainberg, HS Hochster, EJ Kim, B George, A Kaylan, EG Chiorean, ... Clinical cancer research 26 (18), 4814-4822, 2020 | 127 | 2020 |
| Response to anti-EGFR therapy in patients with BRAF non-V600–mutant metastatic colorectal cancer R Yaeger, D Kotani, S Mondaca, AR Parikh, H Bando, EE Van Seventer, ... Clinical Cancer Research 25 (23), 7089-7097, 2019 | 125 | 2019 |
| Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial J Tian, JH Chen, SX Chao, K Pelka, M Giannakis, J Hess, K Burke, ... Nature medicine 29 (2), 458-466, 2023 | 109 | 2023 |
| Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers AR Parikh, A Mojtahed, JL Schneider, K Kanter, EE Van Seventer, ... Clinical Cancer Research 26 (8), 1877-1885, 2020 | 101 | 2020 |
| Analysis of DNA damage response gene alterations and tumor mutational burden across 17,486 tubular gastrointestinal carcinomas: implications for therapy AR Parikh, Y He, TS Hong, RB Corcoran, JW Clark, DP Ryan, L Zou, ... The Oncologist 24 (10), 1340-1347, 2019 | 82 | 2019 |
| The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer JE Berchuck, F Facchinetti, DF DiToro, I Baiev, U Majeed, S Reyes, ... Annals of Oncology 33 (12), 1269-1283, 2022 | 79 | 2022 |
| Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer M Hazar-Rethinam, M Kleyman, GC Han, D Liu, LG Ahronian, ... Cancer discovery 8 (4), 417-427, 2018 | 77 | 2018 |
